 |
|
|
|
 |
A Phase III Study of ABVD with or without Rituximab for Patients with Advanced-Stage Classical Hodgkin Lymphoma with Poor-Risk Features
[Protocol 08-063]
- Full Title :
- A RANDOMIZED PHASE II STUDY OF RITUXIMAB WITH ABVD VERSUS STANDARD ABVD FOR PATIENTS WITH ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA WITH POOR RISK FEATURES (IPS SCORE >2)
- Purpose :
ABVD is a standard treatment for Hodgkin lymphoma that includes the drugs Adriamycin (doxorubicin), Velban (vinblastine), bleomycin, and dacarbazine. Rituximab is a drug used to treat non-Hodgkin lymphoma. Recent information suggests that Hodgkin lymphoma is derived from B cells; there may be a reservoir of memory B cells which can be attacked by rituximab, improving the response and remission rate.
The purpose of this study is to compare the effectiveness of standard ABVD treatment with ABVD plus rituximab in newly diagnosed patients with stage III or IV Hodgkin lymphoma. Patients will be randomly assigned to receive one treatment regimen or the other; their response to treatment will be evaluated using positron emission tomography (PET scans).
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have been newly diagnosed with stage III or IV Hodgkin lymphoma.
- Patients may not have received previous chemotherapy or radiation therapy for Hodgkin lymphoma.
- Patients must be older than age 16.
For more information and to inquire about eligibility for this study, please contact Dr. Carol Portlock at 212-639-8109.
|
|
|
|
|
